UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Clinical trial NCT04382664 · COMPLETED

Trial details

NCT number: NCT04382664
Sponsor: Ultimovacs ASA
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Melanoma

Start date: 2020-05-27
Primary completion: 2024-01-11
Enrollment: 156

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.